Slide 1: Financial Results Analysis
Financial Results Analysis Quarter & Half Year Ended September 30, 2011
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Quarterly Results Analysis
Quarterly Results Analysis 22
Slide 4: Financial Highlights – Q2'FY12
Financial Highlights – Q2’FY12 • Revenue of Rs. 1,048crs for Q2’FY12 • Growth of 22% YoY • Revenue from Products at Rs. 833crs, grew 25% YoY • Revenue from Services Business at Rs. 215crs, grew 12% YoY • EBITDA at Rs. 241crs in Q2’FY12, up 58% YoY • Margins at 23.0% for the quarter, grew 520bps YoY
Slide 5: Income Statement – Q2'FY12
Income Statement – Q2’FY12 Particulars Q2'FY11 Q2'FY12 YoY Growth (Rs Crs) (%) Net Sales 859 1,048 22% Other operating Income 1 2 Income from Operations 860 1,050 22% Total Expenditure 712 812 14% Operating Profit 148 238 61% Other Income 4 3 EBITDA including Other Income 152 241 58% Depreciation 49
Slide 6: Revenue Analysis – Business wise – Q2'FY12
Revenue Analysis – Business wise – Q2’FY 12 Q2'FY11 Q2'FY12 Revenue YoY (Rs crs) Mix (%) Growth % Life Science Ingredients (LSI) 556 592 56% 6% Generics (GX) 110 241 23% 118% Life Science Products 666 833 79% 25% CMO 139 154 15% 11% DDDS 51 58 6% 13% Others 3 3 0% 4% Life Science Services 193 215 21
Slide 7: Highlights – Life Science Products – Q2'FY12
Highlights – Life Science Products- Q2’FY12 Life Science Products Revenue at Rs. 833crs, contributed 79% to Net Sales • Grew 25% YoY driven by volume and positive price variance of 26% 1. Life Science Ingredients – Rs. 592crs, 56% of Revenue Mix • Constitutes APIs, Nutrition Ingredients, PPES and Li
Slide 8: Highlights – Life Science Services – Q2'FY12
Highlights – Life Science Services- Q2’FY12 Life Science Services Business Revenues at Rs. 215cr in Q2’FY12 • Contributed 21% share to Net Sales • Grew 12% YoY 1. CMO Services of Sterile and Non-sterile at Rs. 154crs • Contributed 15% to revenue mix, grew 11% YoY • Strategic initiatives on improved
Slide 9: Revenue Analysis – Geography wise – Q2'FY12
Revenue Analysis – Geography wise- Q2’FY12 (Rs crs) Q2' FY11 Q2' FY12 Mix % YoY % India 260 318 30% 22% International 599 730 70% 22% USA & Canada 315 422 40% 34% Europe & Japan 146 186 18% 27% China 74 66 6% -11% Emerging Markets 64 56 5% -12% Net Sales 859 1,048 100% 22% • 70% of Sales from Intern
Slide 10: Operating Expenditure Analysis – Q2'FY12
Operating Expenditure Analysis – Q2’FY12 Expenses YoY Q2’FY11 % of Sales Q2’FY12 % of Sales (Rs Crs) Growth % Material 379 44% 438 42% 16% Manufacturing 72 8% 84 8% 16% Staff 181 21% 206 20% 14% SG & A 80 9% 86 8% 7% Exchange Loss/ (gain) 0 0% -2 0% Total expenses 712 82% 812 77% 14% • Share of Mate
Slide 11: EBITDA Analysis Q2'FY12
EBITDA Analysis Q2’FY12 Q2’FY11 Q2’FY12 YoY Growth % Products 161 223 38% Services 5 36 577% Business EBITDA 166 259 56% Corp. Allocations 14 18 Reported EBITDA 152 241 58% Margins (%) Q2’FY11 Q2’FY12 bps variance Products 24.2% 26.8% 260 Services 2.8% 16.7% 1390 Consolidated 17.8% 23.0% 520 Company
Slide 12: Half Yearly Results Analysis
Half Yearly Results Analysis 11 11
Slide 13: Financial Highlights – H1'FY12
Financial Highlights – H1’FY12 • Revenue of Rs. 1,992crore for H1’FY12, growth of 19% YoY in H1’FY12 • Revenue from Products at Rs. 1,572crs grew 22% • Revenue from Services Business at Rs. 420crs grew 8% • EBITDA at Rs. 431crore in H1’FY12, up 46% • Margins at 21.7% for the half year, grew 400bps •
Slide 14: Income Statement – H1'FY12
Income Statement – H1’FY12 Particulars H1'FY 11 H1'FY 12 YoY Growth (Rs Crs) (%) Net Sales 1,677 1,992 19% Other operating Income 2 6 Income from Operations 1,679 1,999 19% Total Expenditure 1,389 1,574 13% Operating Profit 290 424 46% Other Income 6 7 EBITDA including Other Income 296 431 46% Depre
Slide 15: Revenue Analysis – Business wise – H1'FY12
Revenue Analysis – Business wise – H1’FY12 H1'FY 11 H1'FY 12 Revenue Mix (%) YoY Growth % Business wise Revenue Rs. Crore Life Science Ingredients (LSI) 1,078 1,200 60% 11% Generics (GX) 209 373 19% 78% Life Science Products 1,287 1,572 79% 22% CMO 278 305 15% 10% DDDS 106 109 5% 4% Others 6 6 0% 0%
Slide 16: Highlights – Life Science Products – H1'FY12
Highlights – Life Science Products- H1’FY 12 Life Science Products Revenue at Rs. 1,572crs in H1’FY12, contributed 79% to Net Sales • Grew 22% YoY driven by volume and positive price variance of 23% 1. Life Science Ingredients – Rs. 1,200crs in H1’FY12, 60% of Revenue Mix • Constitutes APIs, Nutriti
Slide 17: Highlights – Life Science Services – H1'FY12
Highlights – Life Science Services- H1’FY12 Life Science Services Business recorded revenue of Rs. 420cr in H1’FY12 • Contributed 21% share to Net Sales • Grew 8% YoY 1. CMO Services of Sterile and Non-sterile injectibles and products at Rs. 305crs • Contributed over 15% to revenue, grew 10% YoY • I
Slide 18: Revenue Analysis – Geography wise – H1'FY12
Revenue Analysis – Geography wise- H1’FY12 (Rs crs) H1'FY 11 H1'FY 12 Mix % YoY % India 508 609 31% 20% International 1,169 1,383 69% 18% USA & Canada 626 762 38% 22% Europe & Japan 268 368 18% 37% China 160 137 7% -14% Emerging Markets 115 116 6% 1% Net Sales 1,677 1,992 100% 19% • 69% of Sales fro
Slide 19: Operating Expenditure Analysis – H1'FY12
Operating Expenditure Analysis – H1’FY12 Expenses YoY H1’FY11 % of Sales H1’FY12 % of Sales (Rs Crs) Growth Material 744 44% 856 43% % 15% Manufacturing 138 8% 162 8% 17% Staff 358 21% 396 20% 11% SG & A 147 9% 159 8% 8% Exchange Loss/ (gain) 2 0% 1 0% -23% Total expenses 1,389 82% 1,574 78% 13% • S
Slide 20: EBITDA Analysis – H1'FY12
EBITDA Analysis – H1’FY12 EBITDA (Rs Crs) H1'FY 11 H1'FY 12 YoY Growth% Products 303 394 30% Services 18 71 301% Business EBITDA 321 465 45% Corp. Allocations 25 34 Reported EBITDA 296 431 46% Margins (%) Bps Variance Products 23.6% 25.0% 140 Services 4.6% 17.0% 1240 Consolidated 17.7% 21.7% 400 Com
Slide 21: Debt Profile
Debt Profile June 30, 2011 September 30, 2011 Change from June- September Foreign Currency Loans ($ Mn) ($ Mn) Standalone 195 219 Subsidiaries 208 195 FCCB 0 0 Total 403 414 11 Change in Foreign Currency Loan Rs. Crs 54 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 652 679 Subsidiaries 0 0 Rupee Loan S
Slide 22: Outlook
Outlook • The overall underlying strength of our business has been strong due to increasing order book position and capacity utilisation in all our business segments • In Second Half, the Company expects to continue to build on the robust sustainable revenue and margin growth momentum recorded in th
Slide 23: Conference Call Details
Conference Call Details Date of the Call: Tuesday, November 1, 2011 Time of the Call: 04:00 pm IST Conference Dial-In Numbers Primary Number: +91 22 6629 0301 Secondary Number: +91 22 3065 0122 The numbers listed above are universally accessible from all networks and all countries. 6000 1221 Availab
Slide 24: For more information
For more information Visit us at www.jubl.com Contact us at nidhi_aggarwal@jubl.com Ph: +91-120 4361002 siddharth@cdr-india.com Ph: +91-22 6645 1209 23 23